Bank of New York Mellon Corp Cuts Stock Position in bluebird bio, Inc. (NASDAQ:BLUE)

Bank of New York Mellon Corp cut its stake in shares of bluebird bio, Inc. (NASDAQ:BLUE) by 95.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 29,073 shares of the biotechnology company’s stock after selling 549,955 shares during the quarter. Bank of New York Mellon Corp’s holdings in bluebird bio were worth $242,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the company. Verition Fund Management LLC purchased a new position in bluebird bio during the 3rd quarter worth $42,000. Captrust Financial Advisors increased its stake in shares of bluebird bio by 48.2% during the third quarter. Captrust Financial Advisors now owns 237,648 shares of the biotechnology company’s stock worth $123,000 after acquiring an additional 77,293 shares during the period. Barclays PLC raised its holdings in bluebird bio by 273.7% during the third quarter. Barclays PLC now owns 252,062 shares of the biotechnology company’s stock worth $130,000 after purchasing an additional 184,605 shares in the last quarter. BNP Paribas Financial Markets lifted its position in bluebird bio by 2,270.2% in the third quarter. BNP Paribas Financial Markets now owns 371,224 shares of the biotechnology company’s stock valued at $193,000 after purchasing an additional 355,562 shares during the period. Finally, FMR LLC boosted its holdings in bluebird bio by 8.1% in the 3rd quarter. FMR LLC now owns 2,481,965 shares of the biotechnology company’s stock valued at $1,289,000 after purchasing an additional 186,903 shares in the last quarter. 87.43% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

BLUE has been the subject of a number of analyst reports. JPMorgan Chase & Co. raised bluebird bio from an “underweight” rating to a “neutral” rating in a research note on Monday, February 24th. Barclays increased their price objective on bluebird bio from $2.00 to $40.00 and gave the stock an “overweight” rating in a research report on Tuesday, December 31st. StockNews.com started coverage on bluebird bio in a report on Friday. They issued a “sell” rating for the company. Baird R W cut shares of bluebird bio from a “strong-buy” rating to a “hold” rating in a research note on Friday, February 21st. Finally, Wells Fargo & Company cut their price target on shares of bluebird bio from $40.00 to $5.00 and set an “equal weight” rating for the company in a report on Monday, February 24th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $51.00.

bluebird bio Stock Up 7.7 %

BLUE opened at $4.08 on Friday. bluebird bio, Inc. has a one year low of $3.56 and a one year high of $28.60. The company has a market cap of $39.67 million, a price-to-earnings ratio of -0.11 and a beta of 0.76. The business’s fifty day moving average is $5.53 and its two-hundred day moving average is $7.75. The company has a debt-to-equity ratio of 0.37, a quick ratio of 0.33 and a current ratio of 0.51.

bluebird bio Company Profile

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.